Lithium citrate

Drug Profile

Lithium citrate

Alternative Names: Lithium citrate tetrahydrate; NP-03; NP03 - Medesis Pharma

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medesis Pharma
  • Class Alkali metals; Antidepressants; Antimanics; Antipsychotics; Light metals; Metals; Neuroprotectants
  • Mechanism of Action Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Huntington's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Huntington's-disease(In volunteers) in France (Buccal)
  • 15 Mar 2016 Biomarkers information updated
  • 20 Aug 2012 Interim pharmacodynamics and adverse events data from a preclinical study in Huntington's disease released by Medesis Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top